This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 17, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (NW Bio), a biotech company developing DCVax® personalized immune therapies for cancer, is pleased to announce the addition of Dr.
Navid Malik and Mr.
Jerry Jasinowski to the Company's Board of Directors. These new members bring to the NW Bio Board longstanding, deep experience in the life sciences industry, advanced manufacturing, and corporate operations and governance.
Navid Malik is the Head of Life Sciences Research for Cenkos Securities Plc. in the UK, and has been one of the most influential analysts in the UK and
Europe over the last decade, covering the life sciences industry worldwide. In 2011, Dr. Malik was awarded two Starmine Awards (awarded each year by Thomson Reuters and the Financial Times): Number One Stock Picker in the European Pharmaceutical Sector, and Number Two Stock Picker in the UK and Ireland Healthcare Sector. Dr. Malik has built life science teams and franchises at multiple large financial institutions in
London, which completed IPOs and secondary stock offerings for small biotech and life sciences companies totaling over
$700 million in recent years, and which also initiated research coverage on dozens of small life sciences companies in addition to covering large pharmaceutical, biologics and healthcare companies. Dr. Malik holds a PhD in Drug Delivery within Pharmaceutical Sciences, as well as degrees in Biomedical Sciences Research (M.Sc.) and Biochemistry and Physiology (B.Sc., joint honors). Dr. Malik also holds an MBA in finance.
Mr. Jasinowski is a nationally recognized chief executive who headed up the largest industrial trade association in the US (the National Association of Manufacturers) for fourteen years, and has decades of experience in leading public and private organizations. He also has extensive board experience across a wide range of manufacturing, technology, and financial firms, including Fortune 1000 and Fortune 500 companies. His board service includes experience on financial, audit and nominating committees. Mr. Jasinowski was also the founder and longtime President of the Manufacturing Institute, providing information and services to the nation's manufacturers. He has extensive experience in economic and strategic analysis, and has authored two books about US-based manufacturing and business. He is extremely knowledgeable about
Washington, DC policy and regulatory affairs relating to a wide range of industries.
Navid Malik and
Jerry Jasinowski bring outstanding expertise, and long and diverse business experience, which will be of great value to NW Bio as we continue to ramp up execution of our business plan and clinical trials in the US and
Europe, build investor confidence, and enhance shareholder value," commented
Linda Powers, CEO of NW Bio. "These two highly accomplished professionals come to NW Bio with the shared vision that DCVax® immune therapies may have the potential to substantially extend the time until progression or recurrence of patients' tumors, and the potential to substantially extend patients' survival times, without debilitating side effects. We are excited to have Dr. Malik and Mr. Jasinowski join the NW Bio team working toward this vision."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company is developing DCVax® dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. For further information about clinical sites and about the Company, please visit the Company's web site at
DisclaimerStatements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-L and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects,""believes,""intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors which could affect the Company's results, are included in the Company's Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.